Gene therapy progress and prospects: gene therapy of lysosomal storage disorders.
Despite disappointments with early clinical studies, there is continued interest in the development of gene therapy for the group of metabolic diseases referred to as lysosomal storage disorders (LSDs). The LSDs are monogenic and several small and large, representative animal models of the human diseases are available. Further, the successful reconstitution of only low and unregulated tissue levels of the affected lysosomal enzymes are expected to be sufficient to correct the disease at least in the case of some of the LSDs. For these reasons, they are perceived as good models for the evaluation of different gene delivery vectors and of different strategies for treating chronic genetic diseases by gene transfer. In this review, we will highlight the progress that has been made over the past 2 years in preclinical research for this group of disorders and speculate on future prospects.
Cheng
S H
SH
Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701-9322, USA.
Smith
A E
AE
D000818:Animals; D000229:Dependovirus / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D006801:Humans; D019272:Leukocyte Elastase / Q000378:metabolism; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D008168:Lung / Q000201:enzymology; D016464:Lysosomal Storage Diseases / Q000378:metabolism / Q000628:therapy*; D020140:Lysosomal Storage Diseases, Nervous System / Q000628:therapy; D023421:Models, Animal; D018482:Muscle, Skeletal / Q000201:enzymology; D012190:Retroviridae / Q000235:genetics; D014161:Transduction, Genetic / Q000379:methods*
D019272:Leukocyte Elastase